𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year

✍ Scribed by Suzan M. M. Verstappen; Johannes W. G. Jacobs; Johannes W. J. Bijlsma; Anton H. M. Heurkens; Christina van Booma-Frankfort; Evert Jan ter Borg; Dick M. Hofman; Maaike J. van der Veen


Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
131 KB
Volume
48
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Objective

To evaluate whether the clinical advantages observed after 1 year in a randomized controlled clinical trial, in which 2 treatment strategies were compared (the early disease‐modifying antirheumatic drug [DMARD] approach versus the pyramid approach), persist after 5 years.

Methods

In this study, 238 patients with recently diagnosed rheumatoid arthritis (RA) were randomized to either the pyramid group (n = 56) or the early DMARD group (n = 182). Patients assigned to the pyramid group received nonsteroidal antiinflammatory drugs for at least 1 year after inclusion (the mean ± SD lag time until first prescription of a DMARD was 14 ± 9 months). Patients in the early DMARD group were treated with a DMARD immediately after inclusion.

Results

After 5 years, data were available for 44 patients in the pyramid group (79%) and 145 patients in the early DMARD group (80%). No prolongation of the clinical advantages in favor of the early DMARD group, as observed after the first year, was demonstrated. Nevertheless, a significantly shorter delay time until complete response and a higher number of patients with overall clinically relevant improvement at several assessment points were observed in the early DMARD group compared with the pyramid group.

Conclusion

The clinical results in favor of the early DMARD group, as observed after the first year, were not as evident after 5 years. This indicates that a more aggressive treatment approach in early RA is required, and that treatment should be continued for a prolonged period of time, in order to maintain the advantages obtained in the first year.


📜 SIMILAR VOLUMES


Impact of initial aggressive drug treatm
✍ Kari Puolakka; Hannu Kautiainen; Timo Möttönen; Pekka Hannonen; Markku Korpela; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

## Abstract ## Objective To compare the efficacy of therapy with a combination of disease‐modifying antirheumatic drugs (DMARDs) versus therapy with a single DMARD in the prevention of work disability in patients with early rheumatoid arthritis (RA). ## Methods In the Finnish Rheumatoid Arthriti

Retardation of joint damage in patients
✍ Markku Korpela; Leena Laasonen; Pekka Hannonen; Hannu Kautiainen; Marjatta Leiri 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

## Abstract ## Objective To evaluate the long‐term frequency of disease remissions and the progression of joint damage in patients with early rheumatoid arthritis (RA) who were initially randomized to 2 years of treatment with either a combination of 3 disease‐modifying antirheumatic drugs (DMARDs

Low-dose prednisolone in addition to the
✍ Björn Svensson; Annelies Boonen; Kristina Albertsson; Désirée van der Heijde; Ca 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB 👁 2 views

## Abstract ## Objective To assess the efficacy of low‐dose prednisolone on joint damage and disease activity in patients with early rheumatoid arthritis (RA). ## Methods At the start of their initial treatment with a disease‐modifying antirheumatic drug (DMARD), patients with early (duration ≤1